



## OPEN ACCESS

EDITED AND REVIEWED BY  
Dieter Steinhilber,  
Goethe University Frankfurt, Germany

\*CORRESPONDENCE  
Stefania Marzocco,  
smarzocco@unisa.it

SPECIALTY SECTION  
This article was submitted to  
Inflammation Pharmacology,  
a section of the journal  
Frontiers in Pharmacology

RECEIVED 12 August 2022  
ACCEPTED 13 September 2022  
PUBLISHED 13 October 2022

CITATION  
Marzocco S, Esposito G, Esposito E and  
Hassan STS (2022), Editorial: Enteric  
inflammation and chronic diseases: Is  
there a link?  
*Front. Pharmacol.* 13:1018144.  
doi: 10.3389/fphar.2022.1018144

COPYRIGHT  
© 2022 Marzocco, Esposito, Esposito  
and Hassan. This is an open-access  
article distributed under the terms of the  
[Creative Commons Attribution License  
\(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or  
reproduction in other forums is  
permitted, provided the original  
author(s) and the copyright owner(s) are  
credited and that the original  
publication in this journal is cited, in  
accordance with accepted academic  
practice. No use, distribution or  
reproduction is permitted which does  
not comply with these terms.

# Editorial: Enteric inflammation and chronic diseases: Is there a link?

Stefania Marzocco<sup>1\*</sup>, Giuseppe Esposito<sup>2</sup>, Emanuela Esposito<sup>3</sup>  
and Sherif T. S. Hassan<sup>4</sup>

<sup>1</sup>Department of Pharmacy, University of Salerno, Fisciano, Salerno, Italy, <sup>2</sup>Department of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome, Rome, Italy, <sup>3</sup>Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Messina, Italy, <sup>4</sup>Department of Applied Ecology, Faculty of Environmental Sciences, Czech University of Life Sciences Prague, Prague, Czechia

## KEYWORDS

enteric inflammation, chronic disease, intestinal homeostasis, inflammatory markers, metabolic inflammation

## Editorial on the Research Topic

### Enteric inflammation and chronic diseases: Is there a link ?

The prevalence of chronic diseases has become one of the most significant global health threats of the 21st century. These conditions have a significant toll on people's quality of life and create both societal and economic burdens. Inflammation is a normal biological defense against infection and tissue damage. Under normal circumstances, the inflammatory response quickly ends after the clearance of infection and injurious agents. However, when inflammation becomes self-perpetuating, it can result in chronic or long-term inflammation and trigger inflammation-mediated damage that contributes to the pathogenesis of several chronic diseases. Growing evidence suggests a close link between inflammation and many chronic health conditions (Germolec et al., 2018). Tackling this problem requires the study of the underlying mechanisms and the development of new drugs and therapeutic approaches.

The articles contributed to this Research Topic cover different aspects related to inflammatory-based diseases by highlighting the underlying mechanisms and diverse pharmacological strategies. Intestinal chronic inflammations, including inflammatory bowel disease (IBD), are among the diseases showing more pronounced increases. These diseases are widespread and impose burdens on healthcare systems worldwide. Experimental studies have also revealed the link between these conditions and other systemic diseases. As the pharmacological options to treat these conditions are limited, research to identify new therapeutic strategies is of great interest. In this Research Topic, Jiang et al. reported the potential activity of Gaudichaudione H, a natural compound isolated from the plant *Garcinia oligantha* Mer., in inhibiting the inflammatory response in macrophages and dextran sodium sulfate (DSS)-induced colitis in mice mainly through the modulation of nuclear factor- $\kappa$ B (NF- $\kappa$ B) and mitogen-activated protein kinase

(MAPK) pathways, suggesting its potential application in IBD and macrophage-related inflammatory disease in general. da Rocha et al. reported the results of a combined *in vitro* and *in vivo* study to explore the modulation effect of pioglitazone, a PPAR $\gamma$  ligand, on IBD inflammation. They demonstrated the pivotal role of Annexin A1 (AnxA1), a glucocorticoid-modulated anti-inflammatory protein, as a mediating factor for the therapeutic properties of pioglitazone against IBD. Moreover, the *in vitro* data from macrophages indicated that the therapeutic action of pioglitazone depends on extracellular signal-regulated kinase (ERK) phosphorylation, which involves AnxA1. Intestinal barrier homeostasis is involved in many diseases at different levels, including the pathogenesis of recurrent urinary tract infections. Stepanova's mini-review article highlights the importance of the cross-talk between intestinal barrier dysfunction and the recurrence of urinary tract infection to guide experimental and controlled studies to clarify the mechanisms underlying the interaction between these conditions. Chronic low-grade inflammation has also been associated with metabolic disorders such as insulin resistance triggered by the excessive production of leukotriene B4 (LTB4), a potent inflammatory lipid mediator, in combination with its receptor BLT1. In this context, Gong et al. examined *in vitro* the effect of berberine on the LTB4–BLT1 axis in the development of inflammation and insulin resistance. Their results suggested that berberine might interfere with BLT1 and alter the LTB4–BLT1 axis, leading to decreased insulin resistance and inflammation. Clinically, septic liver injury is associated with severe systemic inflammation and multiple organ dysfunction syndromes. Yu et al. investigated the pharmacological effect of dexmedetomidine (DEX), a highly selective  $\alpha_2$ -adrenoreceptor agonist, against septic liver injury. Their results suggested that DEX might protect against cecal ligation and puncture (CLP)-induced liver injury, highlighting a novel mechanism in which DEX improves autophagy, which reduces the inflammatory responses in CLP-induced liver injury by regulating the adenosine monophosphate-activated protein kinase/Sirtuin 1 (AMPK/SIRT1) signaling pathway.

## Reference

Germolec, D. R., Shipkowski, K. A., Frawley, R. P., and Evans, E. (2018). Markers of inflammation. *Methods Mol. Biol.*, 1803, 57–79. doi:10.1007/978-1-4939-8549-4\_5

Finally, the Guest Editors thank all the authors who have contributed to this Research Topic and provided interesting ideas, approaches, and results, which offer a platform upon which other researchers can build.

## Author contributions

Writing—original draft preparation, SM, GE, SH, and EE; writing—review and critical editing, SM, GE, EE, and SH. All authors have read and agreed to the published version of the manuscript.

## Acknowledgments

The authors are thankful to the editorial staff of Frontiers in Pharmacology for their excellent assistance with the Research Topic “Enteric Inflammation and Chronic Diseases: Is There a Link?”.

## Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.